RECENT PUBLICATIONS

2008

Zammit G.K. Zolpidem Extended-Release: Therapy for Sleep Induction and Sleep Maintenance Difficulties. Expert Opin. Drug Metab. Toxicol. Vol 4, No.3: 325-331. 2008

2007

Zammit G.K. Ramelteon: A Novel Hypnotic Indicated for the Treatment of Insomnia. Psychiatry. Vol 4, No. 9. 36-42. September 2007

Zammit G.K. Balance Assessment After Nighttime Awakenings in Healthy Older Adults With and Without Zolpidem Administration. Presented at Society For Neuroscience, 37th Annual Meeting. November 2007

Zammit G.K. The Prevalence, Morbidities, and Treatments of Insomnia. Neurological Disorders: Drug Targets. Vol. 6: 3-16.

Erman M, Krystal A, Zammit G.K., Soubrane C, Roth T. Long-term Efficacy of Zolpidem Extended-Release in the Treatment of Sleep Maintenance and Sleep Onset Insomnia with Improvements in Next-Day Functioning. SLEEP. Vol. 30, Abstract Suppl: A241.

Gangwisch JE, Heymsfield SB, Boden-Albala B, Buijs RM, Kreier F, Pickering TG, Rundle AG, Zammit G.K., Malaspina D. Sleep Duration as a Risk Factor for Diabetes Incidence in a Large US Sample. SLEEP. Vol. 20, No. 12.

Skopicki HA., Sackner-Bernstein J. Teaching Failure: What Fellows Want To Know. American College of Cardiology.

Sackner-Bernstein J., Hirshkowitz M, Schmidt-Nowara W., Chervin RD, Richter RW. Modafinil Does Not Affect Cardiovascular Safety in Patients with Preexisting Hypertension and Excessive Sleepiness-Associated Obstructive Sleep Apnea. American Thoracic Society.

Zammit, G. K. 2007). The prevalence, morbidities, and treatments of insomnia.  CNS Neurological Disorders: Drug Targets, 6, 3 – 16.

Gangwisch, J. E., Heymsfield, S. B., Boden-Albala, B., Buijs, R. M., Kreier, F., Pickering, T. G., Rundle, A. G., Zammit, G. K., Malaspina, D. (2007).  Sleep duration as a risk factor for diabetes incidence in a large US sample, Sleep, 30, 1667 – 1673.

Zammit, G. K.  (2007).  Ramelteon: A novel hypnotic indicated for the treatment of insomnia.  Psychiatry, 4, 36 – 42.

Roth T., Zammit G.K., Scharf M., Farber R.  (2007).  Efficacy and Safety of As-Needed, Post Bedtime Dosing with Indiplon in Insomnia Patients with Chronic Difficulty Maintaining Sleep.  Sleep; 30(12):1731-1738.

Gangwisch, J. E., Heymsfied, S. B., Boden-Albala, B., Buijs, R. M., Kreier, F., Pckering, T. G., Rundle, A. G., Zammit, G. K., Malaspina, D.  (in preparation).  Sleep duration associated with mortality in elderly, but not middle-aged adults in a large U.S. sample” or “Age differences in the association between sleep duration and mortality in a large U.S. sample.

Najib, J. & Zammit, G. K. (in preparation).  Eszopiclone: Efficacy and Safety.  In Pandi-Perumal, Verster, Monti, Lader, & Langer (Eds.), Sleep Disorders: Diagnosis and Therapeutics. 

Greenblatt, D., Harmatz, J., Zammit, G.K., Accomando, W., Sprenger, K., & Aneiro, L.  (2007).  Pharmacokinetic-Pharmacodynamic Effects of NG2-73, A Novel GABA(A) Agonist and Zolpidem.  Sleep, 30, Abstract Supplement, A40.

Zammit, G., Rice, K., Accomando, W., Sprenger, K., & Aneiro, L.  (2007). Effects of NG2-73 on Sleep Onset, Quality and Next Day Function in a Transient Insomnia Study.  Sleep, 30, Abstract Supplement, A239.

Erman, M., Krystal, A., Zammit, G., Soubrane, C., & Roth, T.  (2007).  Long-term efficacy of zolpidem extended-release in the treatment of sleep maintenance and sleep onset insomnia with improvements in next-day functioning.  Sleep, 30, Abstract Supplement, A241.

Erman, M., Krystal, A., Zammit, G., Soubrane, C., & Roth, T.  (2007).  No evidence of rebound insomnia in patients with chornic insomnia treated with zolpidem extended-release 12.5 mg administered “as needed” 3 – 7 nights/week for 6 months.  Sleep, 30, Abstract Supplement, A241.

Wang-Weigand, S., Zammit, G., & Peng, X.  (2007).  Effect of Ramelteon on middle-of-the-night balance, mobility, and memory performance in older adults.  Sleep, 30, Abstract Supplement, A244.

2006

Erman M, Seiden D, Zammit G.K., Sainati S, Zhang J. An Efficacy, Safety, and Dose-Response Study of Ramelteon in Patients with Chronic Primary Insomnia. Sleep Medicine. Vol. 7: 17-24.

Walsh JK, Zammit G.K., Schweitzer PK, Ondrasik J, Roth T. Tiagabine Enhances Slow Wave Sleep and Sleep Maintenance in Primary Insomnia. Sleep Medicine. Vol. 7: 155-161.

Zammit G.K. HD-16: Measuring Quality of Life in Insomnia. Insom. Vol. 7: 33-35.

Ghassibi J, Freeman J, Zammit G.K., Ghassibi M. Correlation Between Daytime Functioning Score and Severity of Obstructive Sleep Apnea (OSA). SLEEP. Vol. 29, Asbtract: A157.

Zammit G.K., Schwartz H, Roth T, Wang-Weigand S, Zhang J. Effect of Ramelteon, a Selective MT1/MT2 Receptor Agonist, in a First-Night-Effect Model of Transient Insomnia. SLEEP. Vol. 29, Asbtract: A238.

Sackner-Bernstein J., Skopicki HA, Aaronson KD; Arthur Feldman (Ed.). Natriuretic Peptides for the Treatment of Acutely Deompensated Heart Failure. Heart Failure: Pharmacologic Management.

Sackner-Bernstein J., Biederman J, Jiang JG, Earl CQ. Cardiovascular Safety of Modafinil-ADHD in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. American Association of Pediatrics.

Greenblatt D, Legangneux E, Harmatz J, Weinling E, Freeman J, Rice K, Zammit G. Dynamics and Kinetics of a Modified-Release Formulation of Zolpidem: Comparison With Immediate-Release Standard Zolpidem and Placebo. Journal of Clinical Pharmacology 2006;46:1469-1480.

Hauptman PJ, Pressler SJ, Sackner-Bernstein J, Ordronneau P, Udelson JE; CASPER Investigators. Rationale and Design of CASPER: Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure. Am J Cardiol. 2006 Oct 2;98(7A):60-6. Epub 2006 Aug 28.

Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA. 2006 Sep 27;296(12):1465-6.

Malli, D., Adachi, M., Ghassibi, J., V., Freeman, J., Lund, S. Correlation between body mass index, apnea/hypopnea index and CPAP pressure requirements in patients with obstructive sleep apnea – presented at the North East Sleep Society, 20th Annual Meeting, March 17, 2006.

Coelho-D’Costa, V., Tsegaye, A. Freeman, J., Lund, S. Comparison of positive airway pressure (PAP) titration via split-night study polysomnography vs full night PAP titration in patients with obstructive sleep apnea - presented at the North East Sleep Society, 20th Annual Meeting, March 17, 2006.

Damian, J., Coelho-D’Costa, V., Narasimhan, M., Freeman, J., Lund, S. Referral patterns from various types of subspecialists to a sleep center & their accuracy in predicting the diagnosis of obstructive sleep apnea” – presented at the North East Sleep Society, 20th Annual Meeting, March 17, 2006.

Zammit, G. K. Gold Standard Celebrates Silver Anniversary. Advance for Managers of Respiratory Care. 39-41. November 2006.

McCall WV, Erman M, Krystal AD., Rosenberg R., Scharf M., Zammit, GK., Wessel T. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion, Vol. 22, No. 9, 2006, 1633-1642.

Zammit, G. K., Corser, B., Doghramji, K., Fry , J. M. , Krystal , A., James , S., & Mangano, R. M. (2006). Sleep and Residual Sedation After Administration of Zaleplon, Zolpidem, and Placebo During Experimental Middle-of-the-Night Awakening. Journal of Clinical Sleep Medicine, 2006 Nov 4. Vol. 2. 417-423.

Zammit, G. K. (2006). Indiplon: A single compound in two formulations for the treatment of insomnia. Future Neurology, 1, 259 – 268.

Gangswisch, J. E. , Heymsfield, S. B. , Boden-Albala, B., Buijs, R. M., Kreier, F., Pickering, T. G., Rundle, A. G., Zammit, G. K., Malaspina, D. (2006). Short sleep duration as a risk factor for hypertension. Analysis of the First National Health and Nutrition Examination Survey. Hypertension, 47, 833 - 839.